Laura Blanco

Pamplona, NC 00489, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Journal: Clinical pharmacology and therapeutics

Published: March 07, 2026

Prognostic impact of cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with risk-adapted protocols.

Prognostic impact of cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with risk-adapted protocols.

Journal: Medicina clinica

Published: January 24, 2025

A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies.

A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies.

Journal: British journal of haematology

Published: July 15, 2024

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Journal: Blood

Published: July 10, 2024

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.

Journal: Blood cancer journal

Published: March 26, 2024

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.

Journal: Blood advances

Published: March 20, 2024

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.

Journal: Nature communications

Published: November 25, 2022

Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients.

Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients.

Journal: Frontiers in immunology

Published: January 26, 2021

Immunologic characterization of COVID-19 patients with hematological cancer.

Immunologic characterization of COVID-19 patients with hematological cancer.

Journal: Haematologica

Published: August 14, 2020

Gene expression workflow to analyze residual leukemic cells in Chronic Lymphocytic Leukemia.

Gene expression workflow to analyze residual leukemic cells in Chronic Lymphocytic Leukemia.

Journal: International journal of laboratory hematology

Published: February 11, 2020

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.

Journal: Leukemia

Published: May 02, 2019

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 22, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026